Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus IA induction vs IA alone in newly diagnosed AML
ChiCTR2000037928Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of decitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Remission rate and MRD negative rate. Started Sep 2020; status: recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000037928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037928.